| Risk of psychopathology in offspring of parents with BD (OPBD)
One approach to identification of early-stage BD is through assessment of developmental pathways of cohorts at high risk for developing BD-or offspring of parents with BD (OPBD). Evidence from family, twin, and adoption studies suggests a heritability rate of up to 85% in monozygotic twins 14 and a 5-to 10-fold higher prevalence of BD amongst first-degree relatives compared to the general population. 15 Population cohort data suggest that offspring of two BD-diagnosed parents have a 5.7-fold higher risk of developing BD compared to offspring with only one bipolar parent, and a 51.9-fold higher risk compared to offspring with no bipolar parents. 16 The significantly elevated risk of BD in OPBD raises the question of whether, within this risk trajectory, there are distinct "ultra-highrisk endophenotypes" and whether OBPD who go on to develop BD progress through recognizable clinical stages en route to a later diagnosis. 17 It is also increasingly apparent that, in addition to elevated risk of later BD, OBPD present with an elevated risk of a broad spectrum of mood and non-mood disorders. 5, 18 Meta-analytic estimates indicate a 2.7-fold increased risk of any mental health disorder and a 4-fold increased risk for any affective disorder in OBPD compared to offspring of healthy parents. However, these estimates are largely derived from historical cohorts identified in the previous century. 19 The risk profile
of OBPD also appears to be distinct from the trajectory of risk for offspring of parents with major mood disorders 20 or non-affective psychoses. 21 This suggests that the risk endophenotypes in OBPD are not reducible to a generalized risk attributable to being raised by a parent with a mental health disorder, 22 and rather may represent a specific vulnerability linked to OPBD status.
Although there is growing evidence that a substantial proportion of OBPD will develop at least one psychiatric disorder, [23] [24] [25] [26] there is scant evidence regarding the developmental progression of the syndromes presented in this cohort 27, 28 and the existing literature is inconsistent regarding the specificity of risk in OBPD. 29 Data on protective factors are also very limited.
| Developmental modelling of OPBD risk
Developmental modelling of risk of onset of BD highlights the importance of depressive, anxiety and/or behavioural disorders as potential precursors to BD in OPBD. 30 However, these precursor disorders are neither necessary for nor specific to development of BD in OPBD. Indeed, existing longitudinal data on OPBD outcomes across different developmental periods report diverse patterns with regard to continuity/discontinuity and specificity of psychopathology between different developmental stages. These findings indicate significant increases in the onset of depressive, anxiety and behavioural problems from early to late childhood, 31 but very few new-onset, recurrent and chronic disorders are reported from early to late adolescence. 32 Ten-year longitudinal data also suggest developmental discontinuity in internalizing problems in OPBD from early childhood to late adolescence, with these difficulties being expressed differently across periods, e.g. self-regulatory deficits in childhood through to thought problems. 28 Longitudinal studies reporting prospective data for cohorts followed through different developmental stages, and data incorporating the peak risk point for BD onset (early adulthood) have only recently emerged. 21, 23, 27, 33 Consequently, it is unclear whether the presence of other disorders in this cohort represent early risk phenotypes, comorbid conditions, or early expressions of BD (e.g. attention deficit hyperactivity disorder [ADHD] 29 ).
In addition, the OPBD literature is hampered by methodological differences in terms of cross-sectional vs longitudinal designs, differences in assessment tools and sample recruitment, 17 and differences in health care systems and provision. 33, 34 As such, the current state of the art research offers inconclusive findings regarding the predictive association of mood or non-mood disorders with the development of BD in OPBD. In addition, the issue of identification and treatment of psychopathology in OBPD raises a number of ethical questions, including whether identification of putative risk endophenotypes is sufficient and specific enough to merit early treatment with psychotropic medication, 35 and whether identification using an endophenotype increases risk of false-positive diagnoses.
| Clinical stage modelling: a developmental psychopathology framework
One heuristic framework to improve the modelling of risk and onset of psychopathology is clinical staging. This framework proposes that disorders develop through a predictable temporal pathway and that stage-appropriate treatment can modify and potentially prevent such a course. 36, 37 These models are usually conceptualized as stages,
evolving from an at-risk stage (Stage 0; e.g. genetic predisposition)
to an end stage (Stage 4; e.g. highly severe and poor prognostic presentation of a disorder 38 ), albeit with the understanding that all stages have an indicative character and may not describe the clinical course for any given individual. 39 Consequently, clinical staging has been identified as a promising approach in understanding the risk endophenotype in OPBD, 27, 40, 41 with a recent review of BD staging in adulthood highlighting its utility, evidence-based focus and dissemination to clinical settings. 42 To date, staging models of BD primarily apply two approaches for describing the progression of risk, focusing either on number of episodes 43 or on level of functioning. 44, 45 In both approaches, the emphasis is mainly on the progress of the illness following the onset of manic-depressive symptoms and only in adult populations. In contrast, Duffy et al. 27, 40, 41 applied a clinical staging model focused on child and adolescent OPBD evaluated from before the onset of the first manic/ hypomanic episode. As illustrated in Figure 1 , this staging model progresses from a "well" state (no presentation of mental health disorders; 
| Aims of the review
Based on the existing evidence of increased risk of BD in OPBD and of the presence of precursor disorders within the pathway to disorder, the aim of the current review was to systematically review and syn- were employed to increase search sensitivity. Citations from the initial research were de-duplicated. The full search history is reported in the Supporting Information (Table S1 ). A leakage strategy was implemented through screening reference lists of all the eligible papers and existing narrative 12 and related systematic reviews. [17] [18] [19] 29, 47 
| METHODS

| Search strategy
| Study selection
Studies were included if they reported (i) a diagnostic assessment of BD in a parent(s) based on a clinical interview; (ii) measures of psychopathology in offspring of a parent(s) with BD based on Diagnostic and Statistical Manual (DSM); and (iii) a mean age of offspring < 18 years at the initial point of offspring psychiatric assessment (where studies reported on longitudinal follow-up, mean age was judged from the mean age at first assessment, but further follow-up points were included).
Papers were eligible for inclusion if they were (iv) published in peerreviewed journals, and (v) conducted between 1970 and May 2016.
Papers were excluded (i) if they reported on first-degree relatives or members of extended families without distinguishing the offspring outcomes based on the relation to the affected member. This exclusion was used to ensure that papers were focused on parent-offspring risk, rather than broad genetic risks. Papers were also excluded (ii) if they reported solely on dimensional outcomes in offspring. This exclusion criterion was used to ensure a homogeneous and validated base of comparison between studies in terms of outcomes. (iii) Single or family case reports, (iv) book chapters, protocols, comments and corrections, and (v) previous systematic reviews and meta-analyses were also excluded.
Once titles and abstracts had been screened, full texts of potentially eligible papers were examined. Where multiple papers Adolescence E arly Adulthood were published from the same cohort, the article reporting most recent follow-up was selected. If remaining papers from these multi-paper cohorts provided supplementary information about the cohort, they were also included. Some of these cohorts also reported follow-up points beyond the cohort mean age of 18 years.
Consequently, for completeness, we reported these data for young adulthood and adulthood in our results. Accuracy of the final list of papers was confirmed by the independent reviewer SO and any disagreements resolved by consensus agreement with the third researcher (AM). 27, 40 ), available data on the mean age of the onset of mood and non-mood disorders were placed on a continuum according to their sequential relation to the onset of BD or manic/hypomanic symptoms. Longitudinal data reporting on the association between onset of mood and non-mood disorders and later onset of BD were also identified.
| Data extraction
| Quality assessment
Quality assessment was conducted using an adapted version of the Agency for Healthcare Research and Quality (AHRQ) checklist. 48 The quality check was applied to all papers that met inclusion criteria, regardless of the cohort. The methodological robustness of the papers was evaluated based on 11 quality criteria. The rating scale is presented in detail in Supporting Information Table S2 . The grading of each item contained the options "yes" (2 points), "partially" (1 point),
"no" (0 points), or "not applicable" (N/A). All applicable items were added up to a "total score", which was then divided by the "maximum (max) score" (if all items applicable: 22 points, if one item not applicable: 20 points; if two items not applicable: 18 points, etc.), to calculate the "percentage score".
The formula used was:
Ten of the 26 eligible papers (39%) were independently rated by another member of the research team (SO). Inter-rater reliability was computed using "ReCal2", which resulted in a Cohen's kappa score of 0.695, indicating a substantial agreement rate. 49 Any discrepancies were reassessed and a consensus agreement was reached between all authors.
| RESULTS
Based on the systematic search described above, 1371 citations 
| Cohort characteristics
Key study characteristics are presented in Table 1 . The total number of the sample was measured based on the number of cohorts With regard to study design, 13 of the 21 cohort studies had a cross-sectional design, six had a longitudinal design, and two generated reports using both designs. OPBD follow-up duration extended from 1 to 16 years beyond the index psychiatric assessment of offspring; therefore, some samples exceeded the mean age of 18 years at the last assessment. The mean age of offspring ranged from 2.4 to 28 years. Of the 16 cohorts with a control group, 10 were recruited from healthy parents ("healthy control group"), one from psychiatrically ill parents ("psychiatrically ill control group") and five from both ("both types control group").
Results from cohort studies were published between 1985 and 2016. This was reflected in the categorical measurement used:
DSM-III or DSM-III-R (k = 6), DSM -IV or DSM-IV-TR (k = 14) and adaptation to both (k = 1). Parental and offspring assessment tools differed slightly for each cohort, with structured clinical interview
Percentage score = total score max score × x 100 for DSM (SCID), schedule for affective disorders and schizophrenia (SADS) and Kiddie schedule for affective disorders and schizophrenia for school-age children (K-SADS) being the predominant measures. There was considerable variability in how specific disorders were grouped in individual papers. Therefore, for our narrative synthesis, we generated a heuristic framework to map specific disorders into broad psychiatric categories (Table 2) . Six cohort studies provided data for all diagnostic categories. The remaining cohort studies provided data on some but not all of the categories of psychiatric disorders covered in our review. Study findings were reported in the form of current prevalence (k = 1), lifetime prevalence (k = 19), cumulative incidence (k = 2) or both lifetime and cumulative incidence (k = 4; see Table 3 ). In the following, prevalence will refer to lifetime prevalence (or cumulative incidence) unless specifically stated otherwise.
| Axis I disorder across all developmental stages
Diagnostic data were available from all 21 cohort studies, with 15 of 21 reporting data on the overall percentage of OPBD presenting with at least one DSM-III or -IV Axis I diagnosis. 13, 20, 21, 23, 24, 26, [32] [33] [34] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] The remaining six cohort studies reported data on DSM diagnoses but did not correct for comorbid diagnoses; therefore, a total percentage could not be generated. 25, 27, 30, 31, 60, 61 Approximately 50% of OPBD individuals in the majority of cross-sectional studies 21, 26, 34, 50, 54, 55, 57, 59 and > 70% in longitudinal studies 23, 32, 33 were assessed as meeting criteria for at least one Axis I disorder. This risk was found to be elevated in OPBD when compared to offspring of healthy parents, regardless of developmental stage and country of origin. 20, 21, 23, 24, 34, 50, 51, [54] [55] [56] In the cohorts with a psychiatrically ill control group, two studies reported OPBD as having a greater rate of Axis I disorders, 57, 59 while two studies reported T A B L E 1 (Continued) no difference between the two groups. 20, 21 Data for proportion of OBPD meeting criteria for mood and non-mood-related disorders are reported in Table 3 , further delineated by developmental stage.
| Early childhood
Five cohort studies 20, 31, 32, 51, 58 provided data for early childhood, with a mean age range from 2.4 31 to 6 20 years. One cohort 51 had a healthy control group and one cohort 31 examined its sample at two time points (at a mean age of 2.4 years and at a mean age of 5.6 years).
| Mood disorders
Bipolar spectrum disorders (BPSDs)
A rate of 2% for BD not otherwise specified in OPBD was reported, 51 which did not significantly differ from that in the offspring of healthy parents.
Unipolar spectrum disorders (UPSDs)
The prevalence in OPBD ranged from 0% 31 to 43%, 58 which was not found to be significantly different from that in the healthy control group. 51 Longitudinal analyses 31 showed a significant increase of depression incidence rates among OPBD over the course of early childhood.
| Non-mood disorders
Anxiety disorders (ADs)
The prevalence in OPBD ranged from 9% 31 to 43%. 58 Only the prevalence of generalized anxiety disorder (GAD
51
) was found to be significantly higher in OPBD compared to the healthy control group.
Longitudinal analyses 31 did not show a significant impact of time on OPBD's incidence rates of anxiety (mainly separation anxiety disorder
[SAD]).
Disruptive behaviour disorders (DBDs)
The prevalence rate ranged from 2% 51 to 43% 58 in OPBD. DBDs both categorically, but also separately for ADHD and for Oppositional Defiant Disorder were found to be more prevalent in OPBD compared to the control group, albeit marginally in the case of Oppositional Defiant Disorder. 51 An increase in the incidence rates of disruptive behaviour in OPBD was observed during this developmental stage. 31 In all diagnostic categories (except for BPSDs), the highest rate was reported for the Rockville cohort, 58 which had a noticeably smaller sample size than the other cohorts (n = 7 OPBD).
| Country of origin
One of the five cohorts in this stage had a non-USA sample. 20 No differences between non-USA and USA cohorts were observed.
| Middle childhood
Ten cohorts 13, 20, [24] [25] [26] 31, 32, 50, 57, 60 provided data for the stage of middle childhood, with a mean age range from 6.4 31 to 11.9 50 years. Four cohort studies had a healthy control group 13, 24, 25, 50 and three cohort studies had a control group of both types. 20, 57, 60 One cohort study 31 examined its sample at two time points (at a mean age of 6.4 and at a mean age of 9.2 years).
| Mood disorders
BPSDs
The prevalence in OPBD ranged from 2% 60 to 74% 13 overall and from 2% 20,50 to 37% 13 in cohort studies specifically reporting for bipolar type I disorder (BD-I). In both cases, the higher percentage belonged to the Cleveland cohort, 13 which recruited its OPBD sample via clinical settings (i.e. in this cohort, the offspring rather than the parents were presenting T A B L E 2 Categories of disorders measured in included papers mapped with specific disorders All percentages are rounded. Bipolar spectrum disorders include: bipolar type I disorder (BD-I), bipolar type II disorder (BD-II), bipolar disorder not otherwise specified (BD NOS) and cyclothymia (Cycl.). Unipolar spectrum disorders include: major: major depressive disorder; minor: dysthymia, adjustment disorder with depressed mood and depression not otherwise specified. Anxiety disorders include: generalized anxiety disorder, separation anxiety disorder, obsessive compulsive disorder, overanxious disorder, post-traumatic stress disorder, social phobia, panic disorder and simple/specific phobias. ADHD, attention deficit hyperactivity disorder; ODD, oppositional defiant disorder; CD, conduct disorder; SLD, sleep disorder; SUD, substance use disorder; CI, cumulative incidence (95% confidence interval).
NS, non-significant; -, not measured. *Significantly different compared to non-psychiatric control group (at least P < 0.05). **Significantly different compared to psychiatric control group (at least P < 0.05). ***Significantly different compared to both control groups as a whole (at least P < 0.05).
a Significantly changed over time.
b
Prevalence rate includes ADHD, learning disorder and cluster A traits.
c Cumulative probability of major definite diagnoses (excluding minor depression and non-diagnosable symptoms).
T A B L E 3 (Continued)
in clinical settings for treatment, which differed from most of the other included studies). The prevalence range without this cohort was 2% 20, 57 found no differences between the rates in OPBD and the healthy control group. Three cohort studies found no differences between the rates in OPBD and in psychiatrically ill control groups.
20,57,60
UPSDs
The prevalence rate in OPBD ranged from 5% 57 to 44%. 31 
| Non-mood disorders
ADs
The prevalence in OPBD ranged from 1% 13 to 44%. 57, 60 In two of the four cohorts with a healthy control group, the prevalence of any AD was significantly higher in OPBD. 25, 50 In two of the three cohorts with both types of control group, 57,60 OPBD presented a significantly higher prevalence of any AD when separately compared with offspring of psychiatrically ill parents and with offspring of healthy parents; meanwhile, in the third cohort, rates of ADs were only significantly higher when compared to the healthy control group. 25 were also found to be significantly higher compared to the cohort's control groups. Longitudinal analyses 31 confirmed a significant increase in anxiety symptoms during this developmental stage.
Attention deficit hyperactivity disorder (ADHD)
The prevalence in OPBD ranged from 4% 13 to 31%. 24 Three cohort studies found a higher incidence of ADHD in OPBD compared to a healthy control group, 24, 25, 50 one cohort study found a higher incidence compared to a psychiatrically ill control group, 60 and one cohort study found a higher incidence compared to offspring of healthy and non-healthy parents as a single control group. 57 Two cohorts reported no significant differences compared to any of the control groups.
13,20
Oppositional defiant disorder (ODD)/conduct disorder (CD)
The prevalence rate in OPBD ranged from 0% 13 to 28%. 31 For cohort studies reporting separately for ODD and CD, the ranges were 7% 57 to 19% 25 and 2% 32 to 7%, 57 respectively. Two cohort studies observed an increased prevalence in OPBD compared to a healthy control group (only for ODD 24, 50 ), and one cohort study found an increased prevalence compared to its combined control group (for ODD and CD 57 ). Four cohort studies did not find any differences between 13, 20, 25, 60 and within (i.e. longitudinally 31 ) their samples.
Substance use disorders (SUDs)
The prevalence rate in OPBD ranged from 0% 13,25 to 9%. 20 No significant difference was found in the SUD incidence between OPBD and any type of control group.
13,20,25
| Country of origin
Two of the 10 cohorts in this stage had a non-USA sample. 59 and two cohorts had both types of control groups. 20, 21 In this developmental stage, one of the cohort studies 34 assessed its sample on current disorder prevalence and therefore it is reported separately.
| Mood disorders
BPSDs
The prevalence in OPBD ranged from 0% was 1% and was not found to be significantly different from that in the healthy control group.
UPSDs
The prevalence in OPBD ranged from 16% 55 to 34%, 25 while the current prevalence assessed in the Bucharest cohort was 8%. 34 The prevalence of MDD ranged from 3% 59 to 22% 32 ). No significant differences were reported in the estimated prevalence of any UPSD between OPBD and a healthy control group in two cohort studies 54, 55 and between OPBD and a psychiatrically ill control group in another two. 21, 59 in AD prevalence.
ADHD
The prevalence in OPBD ranged from 5% 52 to 40%, 27 while the current incidence was 21%. 34 Three cohort studies found a significantly higher rate of ADHD in OPBD compared to a healthy control group (for lifetime 21, 25 and current 34 prevalence). Two cohort studies found no difference between OPBD and a healthy control group 54, 55 and one cohort found no difference between OPBD and a psychiatrically ill control group. 21 
ODD/CD
The prevalence in OPBD ranged from 3% 21 to 34% 61 
| Country of origin
Six of the 13 cohorts in this stage had a non-USA sample.
20,21,34,52,54,55
The main difference compared to the USA cohorts was observed in the diagnostic category of BPSDs. Non-USA cohort studies reported a prevalence of <5% and a non-significant difference compared to the control group, in contrast to the USA cohort studies which reported a prevalence of >7% (in four of five cohorts) and a significantly higher risk for OPBD.
25,30,59
| Early adulthood/adulthood
Seven cohort studies 20, 23, 25, 27, 32, 33, 50, 53, 62 provided psychiatric followup data for early adulthood/adulthood with a mean age range from 18 50 to 28 33 years. Three cohorts had a healthy control group 23, 25, 27, 50 and one cohort had a control group of both types 20, 62 . 
| Mood disorders
UPSDs
The prevalence of MDD in OPBD ranged from 10% 53 to 37% 62 and that of minor mood disorders from 9% 62 to 30%. 27 One cohort study observed a higher risk in OPBD compared to the healthy control group for both categories, 23 one cohort study for none of the categories, 62 and one study only for MDD. 27 There were no differences reported compared to the psychiatrically ill control group. 23 and OCD 25 compared to the healthy control group.
ADHD
The prevalence in OPBD ranged from 5% 33,53 to 22%. 25 Two cohort studies found a significantly higher risk in OPBD compared to a healthy control group. 23, 25 Two did not find a higher risk compared to both healthy 27, 62 and psychiatrically ill control groups. 62 
ODD/CD
The prevalence in OPBD ranged from 2% 27 to 7%. 33, 53 For ODD this was 15% 62 to 33% 25 and for CD this was 10% 23 to 12%. 62 Only one 23 of the four cohort studies with a control group reported a significantly higher risk in OPBD (vs the healthy group and only for ODD).
SUD
The prevalence in OPBD ranged from 14% 25 to 30%. 27 Two of the cohort studies reported an increased risk compared to the healthy control group. 23, 27 Two did not find any difference 25, 62 compared to the control groups.
| Country of origin
Four of the seven cohorts in this stage had a non-USA sample 20, 33, 27, 53, 62 . The main differences were found in the non-mood disorders, where overall the non-USA cohorts reported non-significant differences in the prevalence of disorders between OPBD and control groups, in contrast to the USA cohorts.
| Disorder onset and clinical staging findings
Two approaches to staging were observed in the literature: staging by reporting of rates of disorder or mean age of onset of symptoms prior and/ or subsequent to onset of BD (cross-sectional cohort studies 25, 26, 61 ), and staging by examination of associations between disorders at one point and their association with disorder onset at subsequent developmental points (longitudinal cohort studies 30, 23, 27, 33 ). The former is a less rigorous approach to staging given that mean age masks variance in age of onset within cohorts; nevertheless, based on the state of the art of the existing literature, we opted to report both staging models so as to gain an insight into broad patterns of developmental risk in OPBD (see Table 4 ).
| Disorder onset
Seven cohort studies reported data on the onset of mood and nonmood disorders in OPBD. 23, [25] [26] [27] 30, 33, 61 Cross-sectional cohort studies
In two of the three cross-sectional cohort studies, 25,61 the following pattern of mean age of disorder onset was observed in OPBD: (i)
non-mood disorders (ADHD, anxiety and behavioural disorders); (ii)
non-bipolar mood disorders (depression and MDD); (iii) mania.
Longitudinal cohort studies
In the four longitudinal cohort studies, the clinical progression of disorders reported for OPBD developing BD was the following: (i) nonmood disorders (ADHD and anxiety, behavioural and sleep disorders, and nonspecific early childhood indicators of distress) prior to the first episode of mania/hypomania 23, 27, 30, 33 and prior to non-bipolar mood disorders 27, 30 ; (ii) non-bipolar mood disorders (especially those in the depressive polarity, such as MDD) prior to mania/hypomania 23, 27, 30, 33 ; (iii) mania/hypomania; and (iv) substance use disorder prior 23 or subsequent 27, 33 to the first hypomanic/manic episode.
Country of origin
The developmental timing of the onset of each psychiatric category varied considerably, with USA (non-Amish) cohorts 23, 25, 26, 61 presenting an overall earlier mean onset of disorders compared to non-USA and Amish cohorts. 27, 30, 33 Specifically, all USA cohorts, 23, 25, 26, 61 except for the Amish cohort, 30 reported a pre-pubertal mean age of onset of mania/hypomania, or a substantial percentage of OPBD (86%) exhibiting the first (hypo)manic episode in childhood (before 12 years old). Non-USA cohort studies 27,33 and the Amish cohort study 30 reported a mean age of onset of the first BD activation episode in late adolescence/young adulthood.
| Clinical staging findings
Among the longitudinal cohort studies that examined cross-lagged associations between a precursor disorder at one developmental point and later onset of (hypo)mania, childhood anxiety was most consistently related to later manic symptoms (see Table 4 ). 27, 30 The mean onset of anxiety disorders was almost 10 years prior to the onset of (hypo)mania. 27, 30 In the Pittsburgh cohort, 23 DBD, MDD and subthreshold manic/hypomanic episodes were significantly associated with the onset of (hypo)mania. However, when statistical analysis was limited to prospective data (for 344/391 participants), only subthreshold manic/hypomanic episodes continued to be associated with subsequent development of BD in OPBD.
| Quality assessment results
An assessment of methodological quality for all studies included in the review is presented in Table 5 with reporting per AHRQ item and for total score. Papers' percentage score ranged from 56% 56 to 90% 50, 51 with a mean of 73% (standard deviation [SD] = 9.9%). The highest scores for methodological quality were reported for the Pittsburgh 23,50,51 and
Lausanne cohorts. 20, 62 The lowest score for methodological quality was reported for the Texas cohort. 56 Across all studies, the main method- 
| DISCUSSION
The current systematic review synthesizes evidence indicating an increased risk of developing a wide range of mood and/or non-mood disorders in OPBD in comparison to offspring of non-bipolar parents.
Our findings update and extend previous reviews, 12, 18, 19 and suggest that there is additional benefit to appraising this risk through a developmental framework. As hypothesized, risk of psychiatric disorder in OPBD progresses along a developmental pattern, and data are broadly supportive of a clinical staging model.
As indicated by previous findings, 18 we report consistently high rates for OPBD experiencing any Axis I disorder across all developmental stages. However, this broadly elevated risk obscures a more complex pattern of risk of specific disorders in which the estimated risk and the mean age of onset of specific disorders are placed along a developmental continuum. Our revised model (Figure 3 ) updates previous clinical staging models; 27 it proposes that developmental risk in OPBD evolves from non-mood disorders in childhood to mood 
| Clinical Stage 1: non-mood disorders
Consistent with earlier models, 27, 40 
| Clinical Stages 2-3: non-bipolar mood disorders
In contrast to earlier models, 27, 40 our synthesis suggests that developmental risk in adolescence may be more accurately represented by a broad "non-bipolar mood disorders" stage, without delineation into minor and major non-bipolar mood disorders. This may be more parsimonious, given that the current review identifies no significant differences between estimated prevalence and onset of minor (dysthymia, adjustment disorder with depressed mood, and depression NOS) and major (MDD) mood disorders in OPBD. We also emphasize that mood disorders, particularly depressive disorders, consistently precede the onset of manic/hypomanic episodes both in longitudinal and in cross-sectional studies. 23, 25, 27, 30, 33, 61 In contrast to previous papers, 27, 40 we synthesized both prospective and retrospective data, and thus we suggest that a broader mood disorders category may have greater clinical utility than delineation into narrower bandings. However, we also note that particularly followed by externalizing and major disturbances. 33, 64 Moreover, although evidence suggests that manic symptoms are more accurately reported by caregiver reports than by self-or teacher reports, 65 in OPBD samples parental mental state may be a confound in assessing OPBD functioning and health status. 66, 67 We also note that labelling of mood and anxiety disorders varied considerably between studies (e.g. unipolar depression, minor depressive disorder and major depressive disorder) and therefore it may be difficult to identify clear patterns for specific sub-classes of non-bipolar mood disorder in OPBD until further large datasets emerge.
| Clinical Stage 4: mania/hypomania
Consistent with existing models, 27,40 our review supports a final stage (Stage 4) representing the onset of "mania/hypomania", for some OPBD individuals. Similar to our concerns regarding labelling of mood disorders, we also note that the existing literature uses the terms BD, BPSD and mania/hypomania interchangeably. This introduces a potential lack of specificity regarding sub-type of BD assessed and separation of first manic/hypomanic symptoms from BD onset. There are also implications for diagnostic accuracy, given that index incidence of mood symptoms in BD often occurred via a depressive episode. 23, 27, 33 We suggest that specificity of the predictive utility of this stage will increase as more cohorts report adult follow-up data. 
| Recurrent substance use disorder
We identified a gradual increase from middle childhood to early adulthood in SUD amongst OPBD, along with an elevated risk com- 
| Limitations
There are a number of limitations in the present review. Firstly, the developmental patterns of risk found to occur in OPBD should be interpreted with caution as most of the included studies had a crosssectional design, and the majority of OPBD had not yet passed through the peak risk period for developing BD. Secondly, the methodological heterogeneity of studies may have influenced the overall findings; specifically, small sample sizes and the lack of control groups in some of the cohorts may have substantially inflated estimates of risk of psychopathology in OPBD. Nevertheless, our quality assessment of the literature indicated a methodologically robust corpus of studies.
Thirdly, the exclusion of dimensional outcomes in OPBD, although applied in order to ensure a comparable baseline between studies, also resulted in omission of subthreshold BD symptoms (e.g. 13). Finally, although we identified studies from Canada, the USA, South America, Europe and western Asia, our own inclusion criteria and the current status of the field may limit the cross-cultural validity and applicability of our findings to the global youth.
| Implications for research
Our review underlines the importance of developmental continuity in understanding the risk of psychopathology and adoption of a developmental framework when assessing at-risk cohorts. However, upscaling developmental research in ultra-high-risk offspring requires tighter methodologies. For instance, assessment and reporting of the mean age of onset of a disorder and of the current estimated prevalence would enable researchers to better delineate risk at specific developmental stages. In addition, using combined data from complementary sources of information (e.g. caregivers, teachers and self-reports) could enhance the accuracy of findings. 68, 69 Our evidence supports and extends existing developmental psychopathology frameworks. 27, 40 However, bearing in mind the limited available data and heterogeneity of the studies included in this systematic review, further research is required to improve the evidence base and generalizability of this model, particularly with regard to longitudinal cohort studies. This would enable the field to more confidently comment on continuity/discontinuity of risk between developmental periods and also relate developmental findings to outcomes for the peak risk period for BD onset, as has been noted for the literature on risk in offspring of schizophrenia-diagnosed parents. 64, 65 Furthermore, there is a parallel literature on neurophysiological markers for BD risk endophenotypes. [86] [87] [88] In this regard, OPBD cohorts offer an ideal research opportunity for examining the role of where appropriate, over medication prescription, given the association of antidepressants and stimulants with the onset of BD. 69 Finally, a move towards early intervention and primary prevention within OPBD would link to broader strategies acknowledging the public health importance of mental health, in the case of both general and indicated interventions.
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